Here's a breakdown of the 2025 clinical trials related to cannabis and cancer, based on the provided information.

The provided information highlights several ongoing clinical trials in 2025 exploring the potential of cannabinoids in cancer treatment. These trials are geographically diverse, spanning the United States, Israel, Australia, and Spain. The focus areas include glioblastoma, triple-negative breast cancer, and pancreatic cancer. It's crucial to note the accompanying caution from the FDA and NCI regarding claims of cannabis curing cancer, emphasizing that while promising evidence is emerging, clinical validation is still in progress.

According to www.iAsk.Ai - Ask AI:

The trials mentioned are:

  • U.S. & Israel: Phase II glioblastoma trials testing CBD-THC combinations.
  • Australia: CBD for triple-negative breast cancer.
  • Spain: Cannabinoid receptor activation in pancreatic cancer.

The FDA and NCI caution against claims of cannabis curing cancer, but promising adjunctive evidence is growing, and clinical validation is ongoing.


Authoritative Sources

  1. Clinical Trials Information. [ClinicalTrials.gov]
  2. National Cancer Institute. [National Cancer Institute]
  3. U.S. Food & Drug Administration. [U.S. Food & Drug Administration]

Answer Provided by iAsk.ai – Ask AI.

Sign up for free to save this answer and access it later

Sign up →

Web Results

Cannabis and Cannabinoids (PDQ®)
https//www.mercy.net › content › mercy › us › en.HealthWisePrintDocumentServletCall
Cannabis and Cannabinoids (PDQ®)
This cancer information summary provides an overview of the use of Cannabis and its components as a treatment for people with cancer-related symptoms caused ...
UCSD Triple-Negative Breast Cancer Clinical Trials for 2025
https//clinicaltrials.ucsd.edu › triple-negative-breast-cancer
UCSD Triple-Negative Breast Cancer Clinical Trials for 2025
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid ...
, ",14 .11[1, 0 8>
https//refe.cohlife.org › !_p › _townsend_NOT_ON_SERVER_2g › townsend_373-4_2014_08-09b_ocr.pdf
, ",14 .11[1, 0 8>
with triple negative breast cancer. While these results in themselves are of great interest, especially to women with triple negative breast cancer, they ...
Cancers, Volume 17, Issue 13 (July-1 2025) – 209 articles
https//www.mdpi.com › 2072-6694 › 17 › 13
Cancers, Volume 17, Issue 13 (July-1 2025) – 209 articles
Background/Objectives: The aim of this case series is to evaluate the outcomes and safety of video-assisted mastectomy, illustrating the harmonious ...
sitemap-202001.xml
https//www.biospace.com › sitemap-202001.xml
sitemap-202001.xml
... phase-ii-national-cancer-institute-contract-to-develop-novel-predictive-test-for-response-to-immunotherapies-for-patients-with-non-small-cell-lung-cancer...
Abstracts for MASCC/AFSOS/ISOO Annual Meeting 2025
https//link.springer.com › content › pdf › 10.1007 › s00520-025-09559-7.pdf
Abstracts for MASCC/AFSOS/ISOO Annual Meeting 2025
Introduction. Chemotherapy-induced nausea and vomiting (CINV) is among the most distressing side effects, with nausea reported by more than 50% of the.